151 related articles for article (PubMed ID: 21255805)
1. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line.
Yoon CY; Park MJ; Lee JS; Lee SC; Oh JJ; Park H; Chung CW; Abdullajanov MM; Jeong SJ; Hong SK; Byun SS; Lee ES; Lee SE
J Urol; 2011 Mar; 185(3):1102-11. PubMed ID: 21255805
[TBL] [Abstract][Full Text] [Related]
2. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Jeon HG; Yoon CY; Yu JH; Park MJ; Lee JE; Jeong SJ; Hong SK; Byun SS; Lee SE
J Urol; 2011 Nov; 186(5):2084-93. PubMed ID: 21944112
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines.
Shen J; Huang C; Jiang L; Gao F; Wang Z; Zhang Y; Bai J; Zhou H; Chen Q
Biochem Pharmacol; 2007 Jun; 73(12):1901-9. PubMed ID: 17445779
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest.
Li GC; Zhang X; Pan TJ; Chen Z; Ye ZQ
Int J Urol; 2006 May; 13(5):581-6. PubMed ID: 16771729
[TBL] [Abstract][Full Text] [Related]
7. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer.
Mukhopadhyay NK; Weisberg E; Gilchrist D; Bueno R; Sugarbaker DJ; Jaklitsch MT
Ann Thorac Surg; 2006 Mar; 81(3):1034-42. PubMed ID: 16488717
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
[TBL] [Abstract][Full Text] [Related]
10. Impaired activity of volume-sensitive Cl- channel is involved in cisplatin resistance of cancer cells.
Lee EL; Shimizu T; Ise T; Numata T; Kohno K; Okada Y
J Cell Physiol; 2007 May; 211(2):513-21. PubMed ID: 17186499
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities.
Byun SS; Kim SW; Choi H; Lee C; Lee E
BJU Int; 2005 May; 95(7):1086-90. PubMed ID: 15839938
[TBL] [Abstract][Full Text] [Related]
12. Ultrastructural change due to acquired cisplatin resistance in human bladder cancer cells.
Yoon SJ; Park I; Kwak C; Lee E
Oncol Rep; 2003; 10(5):1363-7. PubMed ID: 12883708
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Earel JK; VanOosten RL; Griffith TS
Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
Ryu H; Jin H; Ho JN; Bae J; Lee E; Lee SE; Lee S
Biol Pharm Bull; 2019; 42(1):66-72. PubMed ID: 30606990
[TBL] [Abstract][Full Text] [Related]
15. Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer.
Li DR; Zhang H; Peek E; Wang S; Du L; Li G; Chin AI
J Urol; 2015 Aug; 194(2):547-55. PubMed ID: 25748177
[TBL] [Abstract][Full Text] [Related]
16. [Potentiation of radiation-induced cell killing by histone deacetylase inhibitor].
Akimoto T
Nihon Rinsho; 2004 Jul; 62(7):1348-54. PubMed ID: 15283155
[TBL] [Abstract][Full Text] [Related]
17. [Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells].
Yang YN; Wang Y; Wang XG; Jiang SJ
Ai Zheng; 2008 Aug; 27(8):816-21. PubMed ID: 18710614
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.
Kim MS; Blake M; Baek JH; Kohlhagen G; Pommier Y; Carrier F
Cancer Res; 2003 Nov; 63(21):7291-300. PubMed ID: 14612526
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.
Mutze K; Langer R; Becker K; Ott K; Novotny A; Luber B; Hapfelmeier A; Göttlicher M; Höfler H; Keller G
Ann Surg Oncol; 2010 Dec; 17(12):3336-43. PubMed ID: 20585871
[TBL] [Abstract][Full Text] [Related]
20. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
